Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22767600 | 1.00 | CA1 (0.32) | CA1CA9 | |
| SCHEMBL12257211 | 0.79 | ALDH1A1 (0.34) | — | |
| SCHEMBL9569613 | 0.78 | PPARD (0.43) | CA1CA9 | |
| SCHEMBL9569608 | 0.78 | PPARD (0.43) | CA1CA9 | |
| SCHEMBL25899674 | 0.77 | PPARG (0.42) | — | |
| SCHEMBL22767821 | 0.75 | AKT1 (0.46) | — | |
| SCHEMBL25899464 | 0.73 | — | — | |
| SCHEMBL30417497 | 0.73 | TRPA1 (0.32) | — | |
| SCHEMBL2573446 | 0.72 | FAAH (0.49) | — | |
| SCHEMBL2567546 | 0.72 | FAAH (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2025-09-25 | — | — | US | disclosed |
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | AVIDITY BIOSCIENCES, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-114375296-A | Nucleic acid polypeptide compositions and uses thereof | 艾维迪提生物科学公司 | 2022-04-19 | — | — | CN | disclosed |
| EP-3980436-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Avidity Biosciences, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | Atrium Therapeutics, Inc. | 2020-12-10 | — | — | US | disclosed |
| WO-2020247782-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | AVIDITY BIOSCIENCES, INC. (US) | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12365704-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | CA1 3848/4885CA9 2410/4885 |
| US-20200385414-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | CA1 3848/4885CA9 2410/4885 |
| US-11578090-B2 | Nucleic acid-polypeptide compositions and uses thereof | POLM, POLN, POLI | CA1 3848/4885CA9 2410/4885 |
| US-20230234978-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | CA1 3848/4885CA9 2410/4885 |
| US-20250296946-A1 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | POLM, POLN, POLI | CA1 3848/4885CA9 2410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.